Kennedy Capital Management LLC bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 165,681 shares of the company's stock, valued at approximately $2,551,000. Kennedy Capital Management LLC owned 1.14% of Inhibrx at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Exchange Traded Concepts LLC acquired a new stake in Inhibrx in the fourth quarter valued at approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of Inhibrx during the fourth quarter valued at approximately $348,000. China Universal Asset Management Co. Ltd. bought a new stake in Inhibrx during the fourth quarter worth $47,000. Rhumbline Advisers purchased a new position in Inhibrx in the fourth quarter worth $228,000. Finally, New York State Common Retirement Fund bought a new position in Inhibrx in the 4th quarter valued at $53,000. 82.46% of the stock is owned by institutional investors.
Inhibrx Price Performance
Shares of INBX remained flat at $11.47 during mid-day trading on Friday. The company's stock had a trading volume of 84,648 shares, compared to its average volume of 202,509. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $34.75. The stock's 50 day moving average price is $13.13 and its two-hundred day moving average price is $14.19.
Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. Sell-side analysts anticipate that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
Read Our Latest Stock Analysis on INBX
Inhibrx Company Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Further Reading
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
